SINO BIOPHARM(HK:01177) 经济观察报·2026-03-20 01:50Core Viewpoint - The Chinese pharmaceutical industry is facing significant challenges in internationalization, particularly in conducting multi-center clinical trials due to high costs and funding limitations. However, it is also experiencing a shift from follower innovation to exploratory innovation, leading to increased global recognition of Chinese innovative drugs [2][3]. Group 1: Current Challenges - Chinese pharmaceutical companies are struggling to conduct Phase III clinical trials internationally due to exorbitant costs, with estimates suggesting that a large Phase III trial could cost up to $1 billion [3]. - The total investment required for a drug to go from research to global market approval is approximately $2.6 billion, with only 1 in 10 products surviving the development process, highlighting the financial risks involved [3]. - Many Chinese companies have attempted to establish R&D centers in Europe and the U.S., but failures in these ventures have severely impacted their cash flow, with one failure being detrimental and two failures nearly crippling [3]. Group 2: Opportunities and Developments - The Chinese innovative drug sector is entering an "engineer dividend era," transitioning from following Western innovations to creating their own, with the transaction scale for external licensing of Chinese innovative drugs reaching $135.655 billion in 2025, marking a historical high [2]. - China has become the second-largest country for the first listing of new molecular entities, indicating a growing global recognition of the value of domestic innovative drugs [2]. - There is a call for establishing a "multi-center clinical mutual recognition system" with markets in Japan, South Korea, the Middle East, and Southeast Asia, allowing Chinese companies to distribute cases across these regions during Phase III trials [3]. Group 3: Strategic Initiatives - The Shanghai government is supporting the establishment of an international development alliance for biopharmaceutical companies, aimed at facilitating the early market entry of Chinese drugs in Asia before expanding to Western markets [4].